Skip to main content

News

Cardiac Sarcoidosis – An Underrecognized Myocardial Disease

Sarcoidosis is a multisystemic, chronic inflammatory disorder involving lymph nodes and lungs characterized by a non-caseating, epithelioid cell granulomatous inflammation of affected organs. Cardiac involvement has been reported in 5-30% depending on the diagnostic criteria.

Read full article (Cardiovasc Med | 2024;27(1):1–3)

 

Evaluation and management of patients with coronary chronic total occlusions considered for revascularisation

Chronic total occlusions (CTOs) of coronary arteries can be found in the context of chronic or acute coronary syndromes; sometimes they are an incidental finding in those apparently healthy individuals undergoing imaging for preoperative risk assessment.

Read full article (EuroIntervention, 2024;20:e174-e184)

Screening and prevention in congenital heart disease: Whom, when, and how?

The treatment of congenital heart disease has been one of the triumphs of modern cardiology and cardiac surgery. Most children born with congenital heart disease now survive to adulthood and this has created a new specialty with many challenges.

Read full article (International Journal of Cardiology Congenital Heart Disease 14 (2023) 100480)

Circulating GDF11 exacerbates myocardial injury in mice and associates with increased infarct size in humans

Acute myocardial infarctions are a common cause of heart failure and early death in the elderly. Recent studies challenge the idea that a molecule called growth differentiation factor 11 (GDF11) superfamily exerts heart-rejuvenating effects, as initially proposed by impactful work.

Read full article (Cardiovascular Research (2023) 00, 1–14)

Effects of SARS-COV-2 infection on outcomes in patients hospitalized for acute cardiac conditions. A prospective, multicenter cohort study

This study sought to assess the effect of concomitant SARS-COV-2 infection on clinical outcomes of hospitalized patients.

Read full article (Front. Cardiovasc. Med., 13 October 2023)

 

Towards personalized cardiovascular care: Global Registry of Acute Coronary Events 3.0 score heralds artificial intelligence era

Accurate risk assessment is key to advance personalized treatment strategies in the heterogeneous group of patients with acute coronary syndromes (ACS).

Read full article (European Heart Journal (2023) 00, 1–2)

Circulating Long Noncoding RNA Signatures Associate With Incident Diabetes in Older Adults: A Prospective Analysis From the VITA Cohort Study

Long noncoding RNAs (lncRNAs) are involved in diabetogenesis in experimental models, yet their role in humans is unclear. The paper investigates whether circulating lncRNAs associate with incident type 2 diabetes in older adults.

Read full article (Diabetes Care 2023;46(6):1239–1244)

Artificial Intelligence and Deep Learning: Wittgenstein beats Plato

Artificial intelligence (AI) is becoming increasingly important in cardiovascular medicine - but how does AI learn? Thomas F. Lüscher and Florian A. Wenzl provide their perspective in the European Heart Journal

Modification of the GRACE Risk Score for Risk Prediction in Patients With Acute Coronary Syndromes

The Global Registry of Acute Coronary Events (GRACE) risk score, a guideline-recommended risk stratification tool for patients presenting with acute coronary syndromes (ACS), does not consider the extent of myocardial injury.

Read full article (JAMA Cardiology, August 2023)

 

Circulating Dipeptidyl Peptidase 3 Predicts Cardiogenic Shock and Mortality in Acute Coronary Syndromes

Circulating dipeptidyl peptidase 3 (cDPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. A new study by Florian A. Wenzl et al. published in the European Heart Journal identified cDPP3 as a novel marker of cardiogenic shock (CS) and increased mortality in patients with (ACS).